<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34864683</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2214-3602</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Journal of neuromuscular diseases</Title><ISOAbbreviation>J Neuromuscul Dis</ISOAbbreviation></Journal><ArticleTitle>Biomarkers for C9orf7-ALS in Symptomatic and Pre-symptomatic Patients: State-of-the-art in the New Era of Clinical Trials.</ArticleTitle><Pagination><StartPage>25</StartPage><EndPage>37</EndPage><MedlinePgn>25-37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JND-210754</ELocationID><Abstract><AbstractText>The development of new possible treatments for C9orf72-related ALS and the possibility of early identification of subjects genetically at risk of developing the disease is creating a critical need for biomarkers to track neurodegeneration that could be used as outcome measures in clinical trials. Current candidate biomarkers in C9orf72-ALS include neuropsychology tests, imaging, electrophysiology as well as different circulating biomarkers. Neuropsychology tests show early executive and verbal function involvement both in symptomatic and asymptomatic mutation carriers. At brain MRI, C9orf72-ALS patients present diffuse white and grey matter degeneration, which are already identified up to 20 years before symptom onset and that seem to be slowly progressive over time, while regions of altered connectivity at fMRI and of hypometabolism at [18F]FDG PET have been described as well. At the same time, spinal cord MRI has also shown progressive decrease of FA in the cortico-spinal tract over time. On the side of wet biomarkers, neurofilament proteins are increased both in the CSF and serum just before symptom onset and tend to slowly increase over time, while poly(GP) protein can be detected in the CSF and probably used as target engagement marker in clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Querin</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institut de Myologie, I-Motion Adult ClinicalTrials Platform, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>APHP, Centre de r&#xe9;f&#xe9;rence desmaladies neuromusculaires Nord/Est/Ile de France, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biferi</LastName><ForeName>Maria Grazia</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Inserm UMRS974, Centre of Research in Myology (CRM), Institut de Myologie, GH Piti&#xe9;Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pradat</LastName><ForeName>Pierre-Francois</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>APHP, D&#xe9;partement de Neurologie, Centre R&#xe9;f&#xe9;rent SLA, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire d'Imagerie Biom&#xe9;dicale, CNRS, INSERM, Sorbonne Universit&#xe9;, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Northern Ireland Centre for Stratified Medicine, Biomedical Sciences Research Institute Ulster University, C-TRIC, Altnagelvin Hospital, Londonderry, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neuromuscul Dis</MedlineTA><NlmUniqueID>101649948</NlmUniqueID><ISSNLinking>2214-3599</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000655624">CACFD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015220">Calcium Channels</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015220" MajorTopicYN="N">Calcium Channels</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066128" MajorTopicYN="N">Gray Matter</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="Y">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066127" MajorTopicYN="N">White Matter</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">ASO</Keyword><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">DPRs</Keyword><Keyword MajorTopicYN="N">DTI</Keyword><Keyword MajorTopicYN="N">FTD</Keyword><Keyword MajorTopicYN="N">MRI</Keyword><Keyword MajorTopicYN="N">PET</Keyword><Keyword MajorTopicYN="N">antisense oligonucleotides</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">brain imaging</Keyword><Keyword MajorTopicYN="N">clinical markers</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">neurofilaments</Keyword><Keyword MajorTopicYN="N">neuroimaging</Keyword><Keyword MajorTopicYN="N">pre-symptomatic</Keyword><Keyword MajorTopicYN="N">symptomatic</Keyword></KeywordList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>5</Day><Hour>21</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34864683</ArticleId><ArticleId IdType="pmc">PMC8842771</ArticleId><ArticleId IdType="doi">10.3233/JND-210754</ArticleId><ArticleId IdType="pii">JND210754</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cruts M, Gijselinck I, Van Langenhove T, van der Zee J, Van Broeckhoven C. Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends Neurosci. 2013;36(8):450&#x2013;9s. doi:10.1016/j.tins.2013.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2013.04.010</ArticleId><ArticleId IdType="pubmed">23746459</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol. 2014;10(11):661&#x2013;70. doi:10.1038/nrneurol.2014.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al.. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245&#x2013;56. doi:10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, Dopper EGP, Waite A, Rollinson S, et al.. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11(4):323&#x2013;30. doi:10.1016/S1474-4422(12)70043-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70043-1</ArticleId><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Isaacs AM. C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol. 2018;14(9):544&#x2013;58. doi:10.1038/s41582-018-0047-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0047-2</ArticleId><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy NA, Arthur KC, Tienari PJ, Houlden H, Chi&#xf2; A, Traynor BJ. Age-related penetrance of the C9orf72 repeat expansion. Sci Rep. 2017;7(1):2116. doi:10.1038/s41598-017-02364-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-02364-1</ArticleId><ArticleId IdType="pmc">PMC5437033</ArticleId><ArticleId IdType="pubmed">28522837</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier C, Barbier M, Camuzat A, Anquetil V, Lattante S, Clot F, et al.. Relations between C9orf72 expansion size in blood, age at onset, age at collection and transmission across generations in patients andpresymptomatic carriers. Neurobiol Aging. 2018;74:234.e1&#x2013;234.e8. doi:10.1016/j.neurobiolaging.2018.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.09.010</ArticleId><ArticleId IdType="pubmed">30337192</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi L, Rossi G, Glionna M, Tonoli E, Piccoli E, Fostinelli S, et al.. C9ORF72 hexanucleotide repeat number in frontotemporal lobar degeneration: a genotype-phenotype correlation study. J Alzheimers Dis. 2014;38(4):799&#x2013;808. doi:10.3233/JAD-131028.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-131028</ArticleId><ArticleId IdType="pubmed">24064469</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Frick P, Neumann M. The neuropathology associated with repeat expansions in the C9ORF72 gene. Acta Neuropathol. 2014;127(3):347&#x2013;57. doi:10.1007/s00401-013-1232-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1232-4</ArticleId><ArticleId IdType="pubmed">24356984</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, et al.. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122(1):111&#x2013;3. doi:10.1007/s00401-011-0845-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0845-8</ArticleId><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappella M, Pradat P-F, Querin G, Biferi MG. Beyond the Traditional Clinical Trials for Amyotrophic Lateral Sclerosis and The Future Impact of Gene Therapy. J Neuromuscul Dis. 2021;8(1):25&#x2013;38. doi:10.3233/JND-200531.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JND-200531</ArticleId><ArticleId IdType="pmc">PMC7902976</ArticleId><ArticleId IdType="pubmed">33074186</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster C, Elamin M, Hardiman O, Bede P. Presympto-matic and longitudinal neuroimaging in neurodegeneration&#x2013;from snapshots to motion picture: a systematic review. J Neurol Neurosurg Psychiatry. 2015;86(10):1089&#x2013;96. doi:10.1136/jnnp-2014-309888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-309888</ArticleId><ArticleId IdType="pubmed">25632156</ArticleId></ArticleIdList></Reference><Reference><Citation>Floeter MK, Traynor BJ, Farren J, Braun LE, Tierney M, Wiggs EA, et al.. Disease progression in C9orf72 mutation carriers. Neurology. 2017;89(3):234&#x2013;41. doi:10.1212/WNL.0000000000004115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004115</ArticleId><ArticleId IdType="pmc">PMC5513817</ArticleId><ArticleId IdType="pubmed">28615433</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Nicholas JM, Cash DM, van Swieten J, Dopper E, Jiskoot L, et al.. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. The Lancet Neurology. 2015;14(3):253&#x2013;62. doi:10.1016/S1474-4422(14)70324-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70324-2</ArticleId><ArticleId IdType="pmc">PMC6742501</ArticleId><ArticleId IdType="pubmed">25662776</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappella M, Ciotti C, Cohen-Tannoudji M, Biferi MG. Gene Therapy for ALS-A Perspective. Int J Mol Sci. 2019;20(18):E4388. doi:10.3390/ijms20184388.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20184388</ArticleId><ArticleId IdType="pmc">PMC6771059</ArticleId><ArticleId IdType="pubmed">31500113</ArticleId></ArticleIdList></Reference><Reference><Citation>Miccio A, Antoniou P, Ciura S, Kabashi E. Novel genome-editing-based approaches to treat motor neuron diseases: Promises and challenges. Mol Ther. 2021;S1525-0016(21)00190-8. doi:10.1016/j.ymthe.2021.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.003</ArticleId><ArticleId IdType="pmc">PMC8753272</ArticleId><ArticleId IdType="pubmed">33823304</ArticleId></ArticleIdList></Reference><Reference><Citation>Mordes DA, Morrison BM, Ament XH, Cantrell C, Mok J, Eggan P, et al.. Absence of Survival and Motor Deficits in 500 Repeat C9ORF72 BAC Mice. Neuron. 2020;108(4):775&#x2013;83.e4. doi:10.1016/j.neuron.2020.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.08.009</ArticleId><ArticleId IdType="pubmed">33022228</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters OM, Cabrera GT, Tran H, Gendron TF, McKeon JE, Metterville J, et al.. Human C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC Transgenic Mice. Neuron. 2015;88(5):902&#x2013;9. doi:10.1016/j.neuron.2015.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.11.018</ArticleId><ArticleId IdType="pmc">PMC4828340</ArticleId><ArticleId IdType="pubmed">26637797</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke JG, Bogdanik L, Muhammad AKMG, Gendron TF, Kim KJ, Austin A, et al.. C9orf72 BAC Transgenic Mice Display Typical Pathologic Features of ALS/FTD. Neuron. 2015;88(5):892&#x2013;901. doi:10.1016/j.neuron.2015.10.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.10.027</ArticleId><ArticleId IdType="pmc">PMC4672384</ArticleId><ArticleId IdType="pubmed">26637796</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Pattamatta A, Zu T, Reid T, Bardhi O, Borchelt DR, et al.. C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD. Neuron. 2016;90(3):521&#x2013;34. doi:10.1016/j.neuron.2016.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.005</ArticleId><ArticleId IdType="pubmed">27112499</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Fusco D, Dinallo V, Marafini I, Figliuzzi MM, Romano B, Monteleone G. Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease. Frontiers in Pharmacology. 2019;10:305. doi:10.3389/fphar.2019.00305.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.00305</ArticleId><ArticleId IdType="pmc">PMC6450224</ArticleId><ArticleId IdType="pubmed">30983999</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang P-W, Pham JT, Haeusler AR, Heusler AR, Mistry NA, et al.. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80(2):415&#x2013;28. doi:10.1016/j.neuron.2013.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.015</ArticleId><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Zhu Q, Gendron TF, Saberi S, McAlonis-Downes M, Seelman A, et al.. Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron. 2016;90(3):535&#x2013;50. doi:10.1016/j.neuron.2016.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.006</ArticleId><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Dodart J-C, Tran H, Berkovitch S, Braun M, Byrne M, et al.. Variant-selective stereopure oligonucleotides protect against pathologies associated with C9orf72-repeat expansion in preclinical models. Nat Commun. 2021;12(1):847. doi:10.1038/s41467-021-21112-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21112-8</ArticleId><ArticleId IdType="pmc">PMC7870851</ArticleId><ArticleId IdType="pubmed">33558503</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang Y-J, Prudencio M, et al.. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci Transl Med. 2017;9(383):eaai7866. doi:10.1126/scitranslmed.aai7866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aai7866</ArticleId><ArticleId IdType="pmc">PMC5576451</ArticleId><ArticleId IdType="pubmed">28356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly CV, Miller TM. Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis. Curr Opin Neurol. 2018;31(5):648&#x2013;54. doi:10.1097/WCO.0000000000000594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000594</ArticleId><ArticleId IdType="pmc">PMC7291817</ArticleId><ArticleId IdType="pubmed">30028737</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R, Liefhebber JM, Garc&#xed;a-Osta A, Miniarikova J, Cuadrado-Tejedor M, Espelosin M, et al.. Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy. Mol Ther Nucleic Acids. 2019;16:26&#x2013;37. doi:10.1016/j.omtn.2019.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.02.001</ArticleId><ArticleId IdType="pmc">PMC6393708</ArticleId><ArticleId IdType="pubmed">30825670</ArticleId></ArticleIdList></Reference><Reference><Citation>Amado DA, Davidson BL. Gene therapy for ALS: A review. Molecular Therapy. 2021 S1525-0016(21)00195-7. doi:10.1016/j.ymthe.2021.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.008</ArticleId><ArticleId IdType="pmc">PMC8636154</ArticleId><ArticleId IdType="pubmed">33839324</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al.. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. New England Journal of Medicine. 2017;377(18):1713&#x2013;22. doi:10.1056/NEJMoa1706198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1706198</ArticleId><ArticleId IdType="pubmed">29091557</ArticleId></ArticleIdList></Reference><Reference><Citation>Taga A, Maragakis NJ. Current and emerging ALS biomarkers: utility and potential in clinical trials. Expert Rev Neurother. 2018;18(11):871&#x2013;86. doi:10.1080/14737175.2018.1530987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2018.1530987</ArticleId><ArticleId IdType="pubmed">30273061</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez EF, Sattler R. Biomarker development for C9orf72 repeat expansion in ALS. Brain Res. 2015;1607:26&#x2013;35. doi:10.1016/j.brainres.2014.09.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2014.09.041</ArticleId><ArticleId IdType="pubmed">25261695</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Vourc&#x2019;h P, Pradat PF, Gordon PH, Andres CR, Corcia P. Further development of biomarkers in amyotrophic lateral sclerosis. Expert Review of Molecular Diagnostics. 2016;16(8):853&#x2013;68. doi:10.1080/14737159.2016.1199277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737159.2016.1199277</ArticleId><ArticleId IdType="pubmed">27275785</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende EL, Jackson JL, White A, Seelaar H, van Blitterswijk M, Van Swieten JC. Unravelling the clinical spectrum and the role of repeat length in C9ORF72 repeat expansions. J Neurol Neurosurg Psychiatry. 2021;92(5):502&#x2013;9. doi:10.1136/jnnp-2020-325377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-325377</ArticleId><ArticleId IdType="pmc">PMC8053328</ArticleId><ArticleId IdType="pubmed">33452054</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B, et al.. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. 2012;11(3):232&#x2013;40. doi:10.1016/S1474-4422(12)70014-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70014-5</ArticleId><ArticleId IdType="pmc">PMC3315021</ArticleId><ArticleId IdType="pubmed">22305801</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Isaacs AM, Mizielinska S, Mead S, Lashley T, Wray S, et al.. C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. The Lancet Neurology. 2015;14(3):291&#x2013;301. doi:10.1016/S1474-4422(14)70233-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70233-9</ArticleId><ArticleId IdType="pubmed">25638642</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien M, Burke T, Heverin M, Vajda A, McLaughlin R, Gibbons J, et al.. Clustering of Neuropsychiatric Disease in First-Degree and Second-Degree Relatives of Patients With Amyotrophic Lateral Sclerosis. JAMA Neurol. 2017;74(12):1425&#x2013;30. doi:10.1001/jamaneurol.2017.2699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2699</ArticleId><ArticleId IdType="pmc">PMC5822189</ArticleId><ArticleId IdType="pubmed">29049464</ArticleId></ArticleIdList></Reference><Reference><Citation>Devenney EM, Ahmed RM, Halliday G, Piguet O, Kiernan MC, Hodges JR, Psychiatric disorders in C9orf72 kindreds: Study of 1,414 family members. Neurology. 2018;91(16):e1498&#x2013;507. doi:10.1212/WNL.0000000000006344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006344</ArticleId><ArticleId IdType="pubmed">30258023</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney CJ, Beck J, Rohrer JD, Lashley T, Mok K, Shakespeare T, et al.. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain. 2012;135(Pt 3):736&#x2013;50. doi:10.1093/brain/awr361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr361</ArticleId><ArticleId IdType="pmc">PMC3286330</ArticleId><ArticleId IdType="pubmed">22366791</ArticleId></ArticleIdList></Reference><Reference><Citation>Poos JM, Russell LL, Peakman G, Bocchetta M, Greaves CV, Jiskoot LC, et al.. Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. Alzheimers Dement (Amst). 2021;13(1):e12185. doi:10.1002/dad2.12185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dad2.12185</ArticleId><ArticleId IdType="pmc">PMC8116844</ArticleId><ArticleId IdType="pubmed">34027016</ArticleId></ArticleIdList></Reference><Reference><Citation>Montembeault M, Sayah S, Rinaldi D, Le Toullec B, Bertrand A, Funkiewiez A, et al.. Cognitive inhibition impairments in presymptomatic C9orf72 carriers. J Neurol Neurosurg Psychiatry. 2020;91(4):366&#x2013;72. doi:10.1136/jnnp-2019-322242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-322242</ArticleId><ArticleId IdType="pubmed">32054668</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore K, Convery R, Bocchetta M, Neason M, Cash D, Greaves C, et al.. A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. Applied neuropsychology Adult 2020;1-8. doi:10.1080/23279095.2020.1716357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23279095.2020.1716357</ArticleId><ArticleId IdType="pubmed">32024404</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertrand A, Wen J, Rinaldi D, Houot M, Sayah S, Camuzat A, et al.. Early Cognitive, Structural, and Microstructural Changes in Presymptomatic C9orf72 Carriers Younger Than 40 Years. JAMA Neurol. 2018;75(2):236&#x2013;45. doi:10.1001/jamaneurol.2017.4266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.4266</ArticleId><ArticleId IdType="pmc">PMC5838615</ArticleId><ArticleId IdType="pubmed">29197216</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; DE, M&#xfc;ller H-P, Finsel J, Weydt P, Knehr A, Winroth I, et al.. Deficits in verbal fluency in presymptomatic C9orf72 mutation gene carriers-a developmental disorder. J Neurol Neurosurg Psychiatry. 2020;91(11):1195&#x2013;200. doi:10.1002/alz.12252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12252</ArticleId><ArticleId IdType="pmc">PMC7569387</ArticleId><ArticleId IdType="pubmed">32855285</ArticleId></ArticleIdList></Reference><Reference><Citation>Malpetti M, Jones PS, Tsvetanov KA, Rittman T, van Swieten JC, Borroni B, et al.. Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. Alzheimers Dement. 2021;17(6):969&#x2013;83. doi:10.1002/alz.12252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12252</ArticleId><ArticleId IdType="pmc">PMC8247340</ArticleId><ArticleId IdType="pubmed">33316852</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, Bokde ALW, Byrne S, Elamin M, McLaughlin RL, Kenna K, et al.. Multiparametric MRI study of ALS stratified for the C9orf72 genotype. Neurology. 2013;81(4):361&#x2013;9. doi:10.1212/WNL.0b013e31829c5eee.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31829c5eee</ArticleId><ArticleId IdType="pmc">PMC3772833</ArticleId><ArticleId IdType="pubmed">23771489</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F, Ferraro PM, Riva N, Spinelli EG, Domi T, Carrera P, et al.. Structural and functional brain signatures of C9orf72 in motor neuron disease. Neurobiology of Aging. 2017;57:206&#x2013;19. doi:10.1016/j.neurobiolaging.2017.05.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.05.024</ArticleId><ArticleId IdType="pubmed">28666709</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Weigand SD, Boeve BF, Senjem ML, Gunter JL, DeJesus-Hernandez M, et al.. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain. 2012;135:794&#x2013;806. doi:10.1093/brain/aws001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws001</ArticleId><ArticleId IdType="pmc">PMC3286334</ArticleId><ArticleId IdType="pubmed">22366795</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;necker S, Neuhofer C, Otto M, Ludolph A, Kassubek J, Landwehrmeyer B, et al.. Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients - An Atlas-Based Volumetric MRI Study. Front Aging Neurosci. 2018;10:45. doi:10.3389/fnagi.2018.00045.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2018.00045</ArticleId><ArticleId IdType="pmc">PMC5863593</ArticleId><ArticleId IdType="pubmed">29599716</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocchetta M, Iglesias JE, Neason M, Cash DM, Warren JD, Rohrer JD. Thalamic nuclei in frontotemporal dementia: Mediodorsal nucleus involvement is universal but pulvinar atrophy is unique to C9orf72. Hum Brain Mapp. 2020;41(4):1006&#x2013;16. doi:10.1002/hbm.24856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.24856</ArticleId><ArticleId IdType="pmc">PMC7267940</ArticleId><ArticleId IdType="pubmed">31696638</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocchetta M, Todd EG, Peakman G, Cash DM, Convery RS, Russell LL, et al.. Differential early subcortical involvement in genetic FTD within the GENFI cohort. Neuroimage Clin. 2021;30:102646. doi:10.1016/j.nicl.2021.102646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2021.102646</ArticleId><ArticleId IdType="pmc">PMC8099608</ArticleId><ArticleId IdType="pubmed">33895632</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SE, Khazenzon AM, Trujillo AJ, Guo CC, Yokoyama JS, Sha SJ, et al.. Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. Brain. 2014;137:3047&#x2013;60. doi:10.1093/brain/awu248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu248</ArticleId><ArticleId IdType="pmc">PMC4208465</ArticleId><ArticleId IdType="pubmed">25273996</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, Chipika RH, Christidi F, Hengeveld JC, Karavasilis E, Argyropoulos GD, et al.. Genotype-associated cerebellar profiles in ALS: focal cerebellar pathology and cerebro-cerebellar connectivity alterations. J Neurol Neurosurg Psychiatry. 2021;92(11):1197&#x2013;205. doi:10.1136/jnnp-2021-326854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-326854</ArticleId><ArticleId IdType="pmc">PMC8522463</ArticleId><ArticleId IdType="pubmed">34168085</ArticleId></ArticleIdList></Reference><Reference><Citation>Schludi MH, May S, Gr&#xe4;sser FA, Rentzsch K, Kremmer E, K&#xfc;pper C, et al.. Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. Acta Neuropathol. 2015;130(4):537&#x2013;55. doi:10.1007/s00401-015-1450-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1450-z</ArticleId><ArticleId IdType="pmc">PMC4575390</ArticleId><ArticleId IdType="pubmed">26085200</ArticleId></ArticleIdList></Reference><Reference><Citation>Floeter MK, Gendron TF. Biomarkers for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Associated With Hexanucleotide Expansion Mutations in C9orf72. Front Neurol. 2018;9:1063. doi:10.3389/fneur.2018.01063.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01063</ArticleId><ArticleId IdType="pmc">PMC6289985</ArticleId><ArticleId IdType="pubmed">30568632</ArticleId></ArticleIdList></Reference><Reference><Citation>Floeter MK, Bageac D, Danielian LE, Braun LE, Traynor BJ, Kwan JY. Longitudinal imaging in C9orf72 mutation carriers: Relationship to phenotype. Neuroimage Clin. 2016;12:1035&#x2013;43. doi:10.1016/j.nicl.2016.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2016.10.014</ArticleId><ArticleId IdType="pmc">PMC5153604</ArticleId><ArticleId IdType="pubmed">27995069</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney CJ, Downey LE, Ridgway GR, Beck J, Clegg S, Blair M, et al.. Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions. Alzheimers Res Ther. 2012;4(5):41. doi:10.1186/alzrt144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt144</ArticleId><ArticleId IdType="pmc">PMC3580398</ArticleId><ArticleId IdType="pubmed">23006986</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, Siah WF, McKenna MC, Li Hi Shing S. Consideration of C9orf72-associated ALS-FTD as a neurodevel-opmental disorder: insights from neuroimaging. J Neurol Neurosurg Psychiatry. 2020;91(11):1138. doi:10.1186/alzrt144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt144</ArticleId><ArticleId IdType="pubmed">32855286</ArticleId></ArticleIdList></Reference><Reference><Citation>Walhout R, Schmidt R, Westeneng H-J, Verstraete E, Seelen M, van Rheenen W, et al.. Brain morphologic changes in asymptomatic C9orf72 repeat expansion carriers. Neurology. 2015;85(20):1780&#x2013;8. doi:10.1212/WNL.0000000000002135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002135</ArticleId><ArticleId IdType="pubmed">26497991</ArticleId></ArticleIdList></Reference><Reference><Citation>Papma JM, Jiskoot LC, Panman JL, Dopper EG, den Heijer T, Donker Kaat L, et al.. Cognition and gray and white matter characteristics of presymptomatic C9orf72 repeat expansion. Neurology. 2017;89(12):1256&#x2013;64. doi:10.1212/WNL.0000000000004393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004393</ArticleId><ArticleId IdType="pubmed">28855404</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Burgh HK, Westeneng H-J, Walhout R, van Veenhuijzen K, Tan HHG, Meier JM, et al.. Multimodal longitudinal study of structural brain involvement in amyotrophic lateral sclerosis. Neurology. 2020;94(24):e2592&#x2013;604. doi:10.1212/WNL.0000000000009498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009498</ArticleId><ArticleId IdType="pmc">PMC7455328</ArticleId><ArticleId IdType="pubmed">32414878</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller H-P, Lul&#xe9; D, Roselli F, Behler A, Ludolph AC, Kassubek J. Segmental involvement of the corpus callosum in C9orf72-associated ALS: a tract of interest-based DTI study. Ther Adv Chronic Dis. 2021;12:20406223211002970. doi:10.1177/20406223211002969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20406223211002969</ArticleId><ArticleId IdType="pmc">PMC7989124</ArticleId><ArticleId IdType="pubmed">33815737</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al.. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74(1):20&#x2013;38. doi:10.1002/ana.23937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23937</ArticleId><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassubek J, M&#xfc;ller H-P, Del Tredici K, Lul&#xe9; D, Gorges M, Braak H, et al.. Imaging the pathoanatomy of amyotrophic lateral sclerosis in vivo: targeting a propagation-based biological marker. J Neurol Neurosurg Psychiatry. 2018;89(4):374&#x2013;81. doi:10.1136/jnnp-2017-316365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316365</ArticleId><ArticleId IdType="pmc">PMC5869447</ArticleId><ArticleId IdType="pubmed">29101254</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Brettschneider J, Ludolph AC, Lee VM, Trojanowski JQ, Del Tredici K. Amyotrophic lateral sclerosis&#x2013;a model of corticofugal axonal spread. Nat Rev Neurol. 2013;9(12):708&#x2013;14. doi:10.1038/nrneurol.2013.221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.221</ArticleId><ArticleId IdType="pmc">PMC3943211</ArticleId><ArticleId IdType="pubmed">24217521</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller H-P, Del Tredici K, Lul&#xe9; D, M&#xfc;ller K, Weishaupt JH, Ludolph AC, et al.. In vivo histopathological staging in C9orf72-associated ALS: A tract of interest DTI study. Neuroimage Clin. 2020;27:102298. doi:10.1016/j.nicl.2020.102298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2020.102298</ArticleId><ArticleId IdType="pmc">PMC7270604</ArticleId><ArticleId IdType="pubmed">32505118</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen J, Zhang H, Alexander DC, Durrleman S, Routier A, Rinaldi D, et al.. Neurite density is reduced in the presymptomatic phase of C9orf72 disease. J Neurol Neurosurg Psychiatry. 2019;90(4):387&#x2013;94. doi:10.1136/jnnp-2018-318994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318994</ArticleId><ArticleId IdType="pubmed">30355607</ArticleId></ArticleIdList></Reference><Reference><Citation>Smallwood Shoukry RF, Clark MG, Floeter MK. Resting State Functional Connectivity Is Decreased Globally Across the C9orf72 Mutation Spectrum. Front Neurol. 2020;11:598474. doi:10.3389/fneur.2020.598474.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.598474</ArticleId><ArticleId IdType="pmc">PMC7710968</ArticleId><ArticleId IdType="pubmed">33329355</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SE, Sias AC, Mandelli ML, Brown JA, Brown AB, Khazenzon AM, et al.. Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers. Neuroimage Clin. 2017;14:286&#x2013;97. doi:10.1016/j.nicl.2016.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2016.12.006</ArticleId><ArticleId IdType="pmc">PMC5349617</ArticleId><ArticleId IdType="pubmed">28337409</ArticleId></ArticleIdList></Reference><Reference><Citation>Waugh RE, Danielian LE, Shoukry RFS, Floeter MK. Longitudinal changes in network homogeneity in presymptomatic C9orf72 mutation carriers. Neurobiology of Aging. 2021;99:1&#x2013;10. doi:10.1016/j.neurobiolaging.2020.11.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2020.11.014</ArticleId><ArticleId IdType="pubmed">33421737</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew S, Atassi N. Positron Emission Tomography Molecular Imaging Biomarkers for Amyotrophic Lateral Sclerosis. Front Neurol. 2019;10:135. doi:10.3389/fneur.2019.00135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00135</ArticleId><ArticleId IdType="pmc">PMC6405430</ArticleId><ArticleId IdType="pubmed">30881332</ArticleId></ArticleIdList></Reference><Reference><Citation>Cistaro A, Pagani M, Montuschi A, Calvo A, Moglia C, Canosa A, et al.. The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. Eur J Nucl Med Mol Imaging. 2014;41(5):844&#x2013;52. doi:10.1007/s00259-013-2667-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-013-2667-5</ArticleId><ArticleId IdType="pubmed">24445987</ArticleId></ArticleIdList></Reference><Reference><Citation>Popuri K, Beg MF, Lee H, Balachandar R, Wang L, Sossi V, et al.. FDG-PET in presymptomatic C9orf72 mutation carriers. Neuroimage Clin. 2021;31:102687. doi:10.1016/j.nicl.2021.102687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2021.102687</ArticleId><ArticleId IdType="pmc">PMC8170157</ArticleId><ArticleId IdType="pubmed">34049163</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vocht J, Blommaert J, Devrome M, Radwan A, Van Weehaeghe D, De Schaepdryver M, et al.. Use of Multimodal Imaging and Clinical Biomarkers in Presymptomatic Carriers of C9orf72 Repeat Expansion. JAMA Neurol. 2020;77(8):1&#x2013;10. doi:10.1001/jamaneurol.2020.1087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1087</ArticleId><ArticleId IdType="pmc">PMC7417970</ArticleId><ArticleId IdType="pubmed">32421156</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F, Rocca MA, Valsasina P, Sala S, Caputo D, Perini M, et al.. A longitudinal diffusion tensor MRI study of the cervical cord and brain in amyotrophic lateral sclerosis patients. Journal of Neurology, Neurosurgery &amp; Psychiatry. 2009;80(1):53&#x2013;5. doi:10.1136/jnnp.2008.154252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2008.154252</ArticleId><ArticleId IdType="pubmed">18931009</ArticleId></ArticleIdList></Reference><Reference><Citation>El Mendili MM, Querin G, Bede P, Pradat P-F. Spinal Cord Imaging in Amyotrophic Lateral Sclerosis: Historical Concepts-Novel Techniques. Front Neurol. 2019;10:350. doi:10.3389/fneur.2019.00350.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00350</ArticleId><ArticleId IdType="pmc">PMC6474186</ArticleId><ArticleId IdType="pubmed">31031688</ArticleId></ArticleIdList></Reference><Reference><Citation>Querin G, El Mendili M-M, Bede P, Delphine S, Lenglet T, Marchand-Pauvert V, et al.. Multimodal spinal cord MRI offers accurate diagnostic classification in ALS. J Neurol Neurosurg Psychiatry. 2018;89(11):1220&#x2013;1. doi:10.1136/jnnp-2017-317214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317214</ArticleId><ArticleId IdType="pubmed">29353238</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Burgh HK, Westeneng H-J, Meier JM, van Es MA, Veldink JH, Hendrikse J, et al.. Cross-sectional and longitudinal assessment of the upper cervical spinal cord in motor neuron disease. Neuroimage Clin. 2019;24:101984. doi:10.1016/j.nicl.2019.101984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2019.101984</ArticleId><ArticleId IdType="pmc">PMC6734179</ArticleId><ArticleId IdType="pubmed">31499409</ArticleId></ArticleIdList></Reference><Reference><Citation>Querin G, Bede P, El Mendili MM, Li M, P&#xe9;l&#xe9;grini-Issac M, Rinaldi D, et al.. Presymptomatic spinal cord pathology in c9orf72 mutation carriers: A longitudinal neuroimaging study. Ann Neurol. 2019;86(2):158&#x2013;67. doi:10.1002/ana.25520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25520</ArticleId><ArticleId IdType="pubmed">31177556</ArticleId></ArticleIdList></Reference><Reference><Citation>Triggs WJ, Menkes D, Onorato J, Yan RS, Young MS, Newell K, et al.. Transcranial magnetic stimulation identifies upper motor neuron involvement in motor neuron disease. Neurology. 1999;53(3):605&#x2013;11. doi:10.1212/wnl.53.3.605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.53.3.605</ArticleId><ArticleId IdType="pubmed">10449127</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, Menon P, &#xd6;zdinler PH, Kiernan MC, Vucic S. Pathophysiological and diagnostic implications of cortical dysfunction in ALS. Nature Reviews Neurology. 2016;12(11):651&#x2013;61. doi:10.1038/nrneurol.2016.140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.140</ArticleId><ArticleId IdType="pubmed">27658852</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuwirth C, Nandedkar S, St&#xe5;lberg E, Barkhaus PE, Carvalho M de, Furtula J, et al.. Motor Unit Number Index (MUNIX): reference values of five different muscles in healthy subjects from a multi-centre study. Clin Neurophysiol. 2011;122(9):1895&#x2013;8. doi:10.1016/j.clinph.2011.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2011.05.014</ArticleId><ArticleId IdType="pubmed">21689981</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuwirth C, Barkhaus PE, Burkhardt C, Castro J, Czell D, de Carvalho M, et al.. Tracking motor neuron loss in a set of six muscles in amyotrophic lateral sclerosis using the Motor Unit Number Index (MUNIX): a 15-month longitudinal multicentre trial. J Neurol Neurosurg Psychiatry. 2015;86(11):1172&#x2013;9. doi:10.1136/jnnp-2015-310509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310509</ArticleId><ArticleId IdType="pubmed">25935892</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanznaster D, de Assis DR, Corcia P, Pradat P-F, Blasco H. Metabolomics Biomarkers: A Strategy Toward Therapeutics Improvement in ALS. Front Neurol. 2018;9:1126. doi:10.3389/fneur.2018.01126.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01126</ArticleId><ArticleId IdType="pmc">PMC6305341</ArticleId><ArticleId IdType="pubmed">30619076</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiani A, Martinelli I, Bello L, Querin G, Puthenparampil M, Ruggero S, et al.. Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: Neurofilament light chain levels in definite subtypes of disease. JAMA Neurology. 2017;74(5). doi:10.1001/jamaneurol.2016.5398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.5398</ArticleId><ArticleId IdType="pmc">PMC5822207</ArticleId><ArticleId IdType="pubmed">28264096</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84(1):130&#x2013;9. doi:10.1002/ana.25276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, Poesen K. Diagnostic and prognostic performance of neurofilaments in ALS. Front Neurol. 2018;doi:10.3389/fneur.2018.01167.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01167</ArticleId><ArticleId IdType="pmc">PMC6345692</ArticleId><ArticleId IdType="pubmed">30713520</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, C9ORF72 Neurofilament Study Group, Daughrity LM, Heckman MG, Diehl NN, Wuu J, et al.. Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis. Ann Neurol. 2017;82(1):139&#x2013;46</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5676468</ArticleId><ArticleId IdType="pubmed">28628244</ArticleId></ArticleIdList></Reference><Reference><Citation>Saracino D, Dorgham K, Camuzat A, Rinaldi D, Rametti-Lacroux A, Houot M, et al.. Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications. J Neurol Neurosurg Psychiatry. 2021;jnnp-2021-326914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8606463</ArticleId><ArticleId IdType="pubmed">34349004</ArticleId></ArticleIdList></Reference><Reference><Citation>Barschke P, Oeckl P, Steinacker P, Shweiki MRA, Weishaupt JH, Landwehrmeyer GB, et al.. Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. J Neurol Neurosurg Psychiatry. 2020;91(5):503&#x2013;11. doi:10.1136/jnnp-2019-322476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-322476</ArticleId><ArticleId IdType="pubmed">32132225</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Lombardi V, Jeromin A, Bowser R, Andersen PM, et al.. Neurofilaments in Pre-Symptomatic ALS and the Impact of Genotype. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7-8):538&#x2013;48. doi:10.1080/21678421.2019.1646769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1646769</ArticleId><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="pubmed">31432691</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmer C, Oeckl P, Weishaupt JH, Volk AE, Diehl-Schmid J, Schroeter ML, et al.. Poly-GP in cerebrospinal fluid links C9orf72-associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD. EMBO Mol Med. 2017;9(7):859&#x2013;68. doi:10.15252/emmm.201607486.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201607486</ArticleId><ArticleId IdType="pmc">PMC5494528</ArticleId><ArticleId IdType="pubmed">28408402</ArticleId></ArticleIdList></Reference><Reference><Citation>Avgerinos KI, Ferrucci L, Kapogiannis D. Effects of monoclonal antibodies against amyloid-&#x3b2; on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer&#x2019;s disease. Ageing Res Rev. 2021;68:101339. doi:10.1016/j.arr.2021.101339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2021.101339</ArticleId><ArticleId IdType="pmc">PMC8161699</ArticleId><ArticleId IdType="pubmed">33831607</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>